Caribou Biosciences
VerifiedBiotechnology company focused on genome engineering and developing technology-based solutions for cells.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
($121m) (Public information from Jun 2024)
Share price
$1.6 CRBU
Berkeley California (HQ)
Deals in current and previous year:
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 114 % | (22 %) | 44 % | 149 % | (72 %) | 2 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (279 %) | (710 %) | (767 %) | (326 %) | (1833 %) | (2102 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (278 %) | (697 %) | (718 %) | (296 %) | (1647 %) | (2126 %) | - |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 278 % | 544 % | 594 % | 325 % | - | - | - |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | $0.0 | round |
| investor investor | $0.0 | round | |
| investor investor investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | $0.0 | round | |
| N/A | $0.0 Valuation: $0.0 73.4x EV/LTM Revenues -26.3x EV/LTM EBITDA | round | |
* | N/A | $125m | Post IPO Equity |
| Total Funding | 000k | ||
Related Content
Recent News about Caribou Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Caribou Biosciences
Edit
exited